vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and TEXAS CAPITAL BANCSHARES INC (TCBI). Click either name above to swap in a different company.
TEXAS CAPITAL BANCSHARES INC is the larger business by last-quarter revenue ($324.0M vs $191.2M, roughly 1.7× Axsome Therapeutics, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs 15.5%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs 10.2%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Texas Capital Bank is a bank headquartered in Dallas, Texas. The bank has branches located in every major city in Texas. Its parent bank holding company is Texas Capital Bancshares. It also operates an online-only banking division, Bask Bank.
AXSM vs TCBI — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $324.0M |
| Net Profit | — | $73.8M |
| Gross Margin | — | — |
| Operating Margin | -33.1% | — |
| Net Margin | — | 22.8% |
| Revenue YoY | 57.4% | 15.5% |
| Net Profit YoY | — | 56.8% |
| EPS (diluted) | — | $1.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | $324.0M | ||
| Q4 25 | $196.0M | $327.5M | ||
| Q3 25 | $171.0M | $340.4M | ||
| Q2 25 | $150.0M | $307.5M | ||
| Q1 25 | $121.5M | $280.5M | ||
| Q4 24 | $118.8M | $229.6M | ||
| Q3 24 | $104.8M | $125.3M | ||
| Q2 24 | $87.2M | $267.0M |
| Q1 26 | — | $73.8M | ||
| Q4 25 | $-28.6M | $100.7M | ||
| Q3 25 | $-47.2M | $105.2M | ||
| Q2 25 | $-48.0M | $77.3M | ||
| Q1 25 | $-59.4M | $47.0M | ||
| Q4 24 | $-74.9M | $71.0M | ||
| Q3 24 | $-64.6M | $-61.3M | ||
| Q2 24 | $-79.3M | $41.7M |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | 40.4% | ||
| Q3 25 | -27.0% | 40.5% | ||
| Q2 25 | -24.5% | 33.2% | ||
| Q1 25 | -46.9% | 21.6% | ||
| Q4 24 | -61.1% | 40.7% | ||
| Q3 24 | -59.8% | -63.8% | ||
| Q2 24 | -89.5% | 21.9% |
| Q1 26 | — | 22.8% | ||
| Q4 25 | -14.6% | 30.7% | ||
| Q3 25 | -27.6% | 30.9% | ||
| Q2 25 | -32.0% | 25.2% | ||
| Q1 25 | -48.9% | 16.8% | ||
| Q4 24 | -63.1% | 30.9% | ||
| Q3 24 | -61.7% | -48.9% | ||
| Q2 24 | -91.0% | 15.6% |
| Q1 26 | — | $1.56 | ||
| Q4 25 | $-0.55 | $2.11 | ||
| Q3 25 | $-0.94 | $2.18 | ||
| Q2 25 | $-0.97 | $1.58 | ||
| Q1 25 | $-1.22 | $0.92 | ||
| Q4 24 | $-1.54 | $1.43 | ||
| Q3 24 | $-1.34 | $-1.41 | ||
| Q2 24 | $-1.67 | $0.80 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | — |
| Total DebtLower is stronger | $70.0M | $878.3M |
| Stockholders' EquityBook value | — | $3.6B |
| Total Assets | $713.6M | $33.5B |
| Debt / EquityLower = less leverage | — | 0.24× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | — | ||
| Q4 25 | $322.9M | — | ||
| Q3 25 | $325.3M | — | ||
| Q2 25 | $303.0M | — | ||
| Q1 25 | $300.9M | — | ||
| Q4 24 | $315.4M | — | ||
| Q3 24 | $327.3M | — | ||
| Q2 24 | $315.7M | — |
| Q1 26 | $70.0M | $878.3M | ||
| Q4 25 | — | $620.6M | ||
| Q3 25 | — | $620.4M | ||
| Q2 25 | — | $620.3M | ||
| Q1 25 | — | $660.5M | ||
| Q4 24 | — | $660.3M | ||
| Q3 24 | — | $660.2M | ||
| Q2 24 | — | $660.0M |
| Q1 26 | — | $3.6B | ||
| Q4 25 | $88.3M | $3.6B | ||
| Q3 25 | $73.7M | $3.6B | ||
| Q2 25 | $73.1M | $3.5B | ||
| Q1 25 | $53.2M | $3.4B | ||
| Q4 24 | $57.0M | $3.4B | ||
| Q3 24 | $92.9M | $3.4B | ||
| Q2 24 | $102.9M | $3.2B |
| Q1 26 | $713.6M | $33.5B | ||
| Q4 25 | $689.8M | $31.5B | ||
| Q3 25 | $669.3M | $32.5B | ||
| Q2 25 | $639.8M | $31.9B | ||
| Q1 25 | $596.7M | $31.4B | ||
| Q4 24 | $568.5M | $30.7B | ||
| Q3 24 | $561.5M | $31.6B | ||
| Q2 24 | $548.2M | $29.9B |
| Q1 26 | — | 0.24× | ||
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.17× | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.19× | ||
| Q4 24 | — | 0.20× | ||
| Q3 24 | — | 0.20× | ||
| Q2 24 | — | 0.21× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
TCBI
Segment breakdown not available.
